ProMIS Neurosciences names Ivana Rubino chief commercial officer
PMN•ProMIS Neurosciences appointed Ivana Rubino chief commercial officer, effective Oct. 5, 2026. She will lead commercial strategy and market preparation for PMN310, including market access planning and launch readiness.
1. Rubino’s new role
Rubino most recently served at Biogen as vice president and global head of Alzheimer’s disease and multiple sclerosis medical. Her earlier roles included senior leadership posts at Biogen across Alzheimer’s programs, as well as medical affairs and commercial roles at Roche.
